Nanobiotix (NASDAQ:NBTX) Stock Price Up 11.8% - What's Next?

Key Points

• NBTX stock price surged by 11.8% during trading, reaching a high of $13.18, with trading volume significantly increased to 76,679 shares, compared to an average of 16,482 shares.
• Research firms have shown optimism, with Leerink Partners setting a price target of $14.00 and HC Wainwright maintaining a "buy" rating for the stock.
• A new institutional investor, Millennium Management LLC, purchased 13,452 shares valued at approximately $39,000, indicating growing institutional interest in the company.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s stock price rose 11.8% on Monday . The company traded as high as $13.18 and last traded at $12.94. Approximately 76,679 shares were traded during mid-day trading, an increase of 365% from the average daily volume of 16,482 shares. The stock had previously closed at $11.57.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Leerink Partners set a $14.00 price target on shares of Nanobiotix in a research report on Thursday. HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a research report on Friday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Nanobiotix Trading Up 4.9%

The firm has a fifty day moving average price of $8.13 and a 200 day moving average price of $5.39.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,452 shares of the company's stock, valued at approximately $39,000. Institutional investors and hedge funds own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.